Navigation Links
ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011
Date:7/21/2011

EXTON, Pa., July 21, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2011 are expected to be released on Thursday, July 28, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2011 second quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until August 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... 2014 ­ RedBrick Health , a fast-growing leader ... announces that EmblemHealth , the New ... now providing the RedBrick Compass health assessment, combined with ... of its members. EmblemHealth is among the first health ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... 1, 2011 Nycomed US Inc. ("Nycomed US") today announced ... Executive Officer and member of the Board for what will ... of the acquisition of Nycomed A/S by Takeda Pharmaceuticals.   ... the newly created position of Chief Operating Officer, and John ...
... signals, for the first time, to assist in braking, ... to the thousands of car accidents that are caused ... technique that attaches electrodes to the scalp , the ... traffic sensors, could detect a driver,s intention to break ...
... Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan ... ( H.R. 2672 ) and ( S. 1423 ), which ... patients with rare diseases by eliminating barriers to innovation. ... therapies are coping with a very rare disease for which ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Put the brakes on using your brain power 2PPTA Praises Legislation That Protects the Treatment of Rare Diseases 2
(Date:4/17/2014)... In the most densely forested and most densely ... centuries of human needs, values and practices. Disturbances associated ... for agriculture and development, have set the stage for ... Service study reports. , The report Five anthropogenic ... needs in the Northern United States was ...
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia ... makes testing safer, easier, faster and cheaper. , ... is commonly found in soils all over the world ... both humans and animals. The bacteria can survive in ... B. anthracis may occur through skin contact, inhalation ...
Breaking Biology News(10 mins):Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... in the brain improves recovery from stroke when injected up ... could be used as an effective stroke drug. A study ... Biology shows that an injection of Granulocyte-Colony Stimulating Factor (G-CSF), ... of neurons and counteract neurone death, reduces the size of ...
... disorders that have led to an epidemic of obesity and ... at Penn State University that are due to be published ... the National Academy of Science and also in the PNAS ... The discovery expands the known taxonomic breadth of metabolic ...
... get a lot easier and cheaper thanks to the work ... , Syed Hashsham, an associate professor in the Department of ... is developing a portable, hand-held device capable of detecting up ... , "This device will give us the ability ...
Cached Biology News:Brain protein improves stroke symptoms in rats, even when injected after 3 days 2Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5Professors to develop hand-held pathogen testing device 2
... 100% capped transcripts with the translation boosting ... of 100% capped (versus 40% to 80% ... in about 2 hours. mScript™ also features ... shown to be up to 50% more ...
Immunogen: Synthetic peptide: M(1) C V P R S G L I L S(11) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Synthetic peptide derived from ... and bovine Math-2. Specificity: Specific ... Human Rat (positive controls: human U251 ... lysates and rat brain homogenates)Storage: Store ...
Biology Products: